These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 22393954

  • 1. Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhang X, Qin Y, Li H, Bai C, Zhu T, Xu J, Wu C, Wu M, Wang C, Song H, Wei L, He J.
    Asian Pac J Cancer Prev; 2011; 12(11):2857-63. PubMed ID: 22393954
    [Abstract] [Full Text] [Related]

  • 2. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
    Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C.
    J Clin Oncol; 2012 Apr 01; 30(10):1114-21. PubMed ID: 22370318
    [Abstract] [Full Text] [Related]

  • 3. Vandetanib for the treatment of non-small-cell lung cancer.
    Wong HL, de Boer RH.
    Expert Opin Pharmacother; 2011 Oct 01; 12(14):2271-8. PubMed ID: 21819274
    [Abstract] [Full Text] [Related]

  • 4. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.
    Qi WX, Tang LN, He AN, Shen Z, Yao Y.
    Lung; 2011 Dec 01; 189(6):437-43. PubMed ID: 21986852
    [Abstract] [Full Text] [Related]

  • 5. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD.
    J Clin Oncol; 2011 Mar 10; 29(8):1059-66. PubMed ID: 21282542
    [Abstract] [Full Text] [Related]

  • 6. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.
    Cochrane Database Syst Rev; 2016 May 25; (5):CD010383. PubMed ID: 27223332
    [Abstract] [Full Text] [Related]

  • 7. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
    Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capó A, Germonpré P, Eberhardt WE, Stockman PK, Kennedy SJ, Ranson M.
    J Clin Oncol; 2009 May 20; 27(15):2523-9. PubMed ID: 19332730
    [Abstract] [Full Text] [Related]

  • 8. [Vandetanib for advanced non-small cell lung cancer: a meta-analysis].
    Tao L, Zhuo W, Yang F, Zhu B.
    Zhongguo Fei Ai Za Zhi; 2012 Mar 20; 15(3):172-8. PubMed ID: 22429581
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
    Liu GF, Li XF, Yu SN, Miao YY, Zhang SH.
    J Cell Physiol; 2019 Apr 20; 234(4):3445-3457. PubMed ID: 30374969
    [Abstract] [Full Text] [Related]

  • 11. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
    Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ.
    Lancet Oncol; 2012 Sep 20; 13(9):897-905. PubMed ID: 22898678
    [Abstract] [Full Text] [Related]

  • 12. Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.
    Xiao YY, Zhan P, Yuan DM, Liu HB, Lv TF, Shi Y, Song Y.
    Clin Oncol (R Coll Radiol); 2013 Jan 20; 25(1):e7-e15. PubMed ID: 23177099
    [Abstract] [Full Text] [Related]

  • 13. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
    Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE.
    Lancet Oncol; 2010 Jul 20; 11(7):619-26. PubMed ID: 20570559
    [Abstract] [Full Text] [Related]

  • 14. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
    Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK.
    J Thorac Oncol; 2013 May 20; 8(5):658-61. PubMed ID: 23584298
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
    Heymach JV, Lockwood SJ, Herbst RS, Johnson BE, Ryan AJ.
    Ann Oncol; 2014 Oct 20; 25(10):1941-1948. PubMed ID: 25057173
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.